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Abstract: Camalexin, the phytoalexin produced in the model plant Arabidopsis thaliana, 
possesses antiproliferative and cancer chemopreventive effects. We have demonstrated that 
the cytostatic/cytotoxic effects of camalexin on several prostate cancer (PCa) cells are due 
to oxidative stress. Lysosomes are vulnerable organelles to Reactive Oxygen Species 
(ROS)-induced injuries, with the potential to initiate and or facilitate apoptosis subsequent 
to release of proteases such as cathepsin D (CD) into the cytosol. We therefore 
hypothesized that camalexin reduces cell viability in PCa cells via alterations in expression 
and activity of CD. Cell viability was evaluated by MTS cell proliferation assay in LNCaP 
and ARCaP Epithelial (E) cells, and their respective aggressive sublines C4-2 and ARCaP 
Mesenchymal (M) cells, whereby the more aggressive PCa cells (C4-2 and ARCaPM) 
displayed greater sensitivity to camalexin treatments than the lesser aggressive cells 
(LNCaP and ARCaPE). Immunocytochemical analysis revealed CD relocalization from the 
lysosome to the cytosol subsequent to camalexin treatments, which was associated with 
increased protein expression of mature CD; p53, a transcriptional activator of CD; BAX, a 
downstream effector of CD, and cleaved PARP, a hallmark for apoptosis. Therefore, 
camalexin reduces cell viability via CD and may present as a novel therapeutic agent for 
treatment of metastatic prostate cancer cells.  
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Molecules 2014, 19 3989 
 
 
Keywords: camalexin; prostate cancer; lysosomes; cathepsin D; phytoalexins 
 
1. Introduction  
Among cancer-related deaths in men, prostate cancer is the second-leading cause in the United 
States despite recently observed decrease in mortality [1]. Once cancers metastasize to other organs, a 
majority of patients die from their tumors as opposed to other causes [2], and this is due in part to the 
tumor ultimately becoming androgen-independent within a median of 18 to 24 months after castration [3]. 
Current treatments have proved inadequate in controlling prostate cancer, and search for novel 
therapeutic agents for the management of this disease has become a priority for researchers. The 
discoveries of the chemopreventive and chemotherapeutic properties of phytochemicals have 
generated considerable interest among cancer researchers. Camalexin (Figure 1) is an indole 
phytoalexin produced in various cruciferous plants upon exposure to environmental stress and plant 
pathogens [4–7].  
Figure 1. The structural formula of camalexin. 
 
It has been shown to possess moderate antifungal and bacteriostatic, as well as antiproliferative and 
cancer chemopreventive properties [7,8]. Our laboratory has shown that camalexin induced apoptosis 
in prostate cancer cells (PCa) through the generation of Reactive Oxygen Species (ROS), and that the 
more aggressive prostate cancer cells with higher levels of endogenous ROS displayed greater 
sensitivity to camalexin treatments evidenced by decreased viability and increased apoptosis as 
compared to the less aggressive prostate cancer cells, while normal epithelial cells were unaffected [9]. 
The generation of intracellular ROS activates several signal transduction pathways leading to 
inflammation, cell cycle progression, apoptosis, migration, and invasion in cancer [10]. Thus, excessive 
production of ROS or inadequacy in a cell’s antioxidant defense system (or both) induces oxidative 
stress with consequent initiation of cellular processes associated with initiation and development of 
many cancers including prostate cancer [11]. Hydrogen peroxide has been shown to increase 
progressively in the lesser aggressive LNCaP prostate cancer cells to its more aggressive sublines C4, 
C4-2 and C4-2B, with concomitant increase in tumorigenic and metastatic potential [12]. Hence, 
several studies were conducted on cancer treatments focusing on ROS inhibition with limited success [13]. 
Conversely, in many preclinical models of cancer, excessive ROS generation triggers pro-apoptotic 
pathways with subsequent apoptosis [14]. Thus, the therapeutic use of pro-oxidants to target prostate 
cancer cells is gaining traction in cancer research [15]. Therefore, compounds that are capable of 
inducing ROS especially in cancer cells warrant further investigation. 
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Apoptosis induced by oxidative stress has been observed in several studies and includes activation 
of cell cycle genes such as p53 and p21 [16–18]. Key players in the regulation of apoptotic cell death 
are the mitochondria, where they coordinate caspase activation through release of cytochrome C. 
Lysosomes, the major cell digestive organelles containing numerous hydrolases that degrade intracellular 
and extracellular materials delivered, has been implicated in the regulation of cell death [19]. Common 
to both mitochondria and lysosomes is their increased membrane permeability resulting in release of 
their contents in the early phase of apoptosis [20]. Varying stimuli induces lysosomal membrane 
permeabilization (LMP) with translocation of enzymes from lysosomal compartment to cytosol, such 
as oxidative stress [21,22], TNF-α [23] and p53 [24]. Among the hydrolytic enzymes released, the 
cathepsins were found to participate in apoptosis following their release into the cytosol. In oxidative 
stress-induced apoptosis, release of cathepsin D (CD) from lysosomes and induction of apoptosis could 
be prevented by the antioxidant α-tocopherol [21]. Deiss et al. have shown that CD anti-sense RNA 
protected Hela cells from IFN-γ- and Fas-induced cell death [25]. Additionally, it has been 
demonstrated that p53 accumulates rapidly after oxidative stress and has two binding sites located at 
the CD promoter gene, and that CD participates in p53-dependent apoptosis [26]. The role of CD in 
apoptosis has been linked to lysosomal release of mature CD into the cytosol, in turn leading to 
mitochondrial release of cytochrome c into the cytosol [27–30], activation of pro-caspases-9  
and -3 [31,32], in vitro cleavage of Bid [33], or Bax activation independent of Bid cleavage [34]. 
Pepstatin A, an aspartate protease inhibitor of CD, could partially delay apoptosis induced by oxidative 
stress [28–31], or even when it was co-microinjected with CD [32]. Therefore, CD could play a key 
role in apoptosis mediated by its catalytic activity. 
Previously, we have shown that prostate cancer cells expressing high levels of ROS (C4-2 and 
ARCaPE cells stably overexpressing Snail) displayed further increase in ROS upon camalexin 
treatment which led to decreased viability and increased apoptosis through activation of caspase-3  
and -7 [9]. Interestingly, the less aggressive cells (LNCaP and ARCaPE with empty vector) were less 
responsive to camalexin and could be induced to be more responsive by addition of exogenous 
hydrogen peroxide [9] thus showing that camalexin mediates its response via ROS. In this current 
study, we have dissected the mechanism of camalexin-induced (apoptosis) decreased-cell viability 
further and shown for the first time that it is mediated through CD. Hence, in our experiments, we 
utilized two prostate cancer progression models, LNCaP/C4-2 and ARCaPE/ARCaPM and found that 
camalexin reduced cell viability in PCa cells that involved relocation of CD from lysosomes to cytosol, 
and increased protein expression of p53, mature CD, Bax, and cleaved PARP. Moreover, pepstatin A, 
the peptide inhibitor of CD activity was able to reverse the effects of camalexin. Targeting lysosomal 
proteases such as CD may therefore provide a great therapeutic potential in especially metastatic 
prostate cancer. 
2. Results and Discussion 
2.1. Camalexin Treatments Decreases Cell Proliferation in the More Aggressive Prostate Cancer Cells 
as Compared to the Lesser Aggressive Cells 
Previously, we have shown that camalexin was more potent in reducing cell viability in C4-2 as 
compared to LNCaP cells suggesting that camalexin was more potent in the more aggressive cell line [9]. 
Confirming these results utilizing CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS 
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assay) we observed that at day 0 for both LNCaP and C4-2 cells, viability was unaffected but on day 3, 
only 50 µM camalexin decreased cell viability in LNCaP by approximately 40% ± 2% (p < 0.01), 
while camalexin decreased C4-2 cell viability by approximately 40% ± 2% (p < 0.001) for 10 and  
25 μM camalexin and 30% ± 5% (p < 0.01) for 50 μM camalexin, respectively (Figure 2A). We also 
tested the effect of camalexin on ARCaPE (epithelial) and ARCaPM (mesenchymal) cell lines that are 
derived from the same parental ARCaP but represent an EMT progression model [35,36]. CellTiter 
96 AQueous One Solution Cell Proliferation Assay (MTS assay) was utilized and the results for day 0 
and day 3 represented. For day 0, both ARCaPE and ARCaPM cells showed no change in viability as 
expected, however, on day 3, camalexin treatment of ARCaPE decreased cell viability by approximately 
23% (p < 0.05) at 25 µM treatment only, while for ARCaPM cells 10, 25 and 50 µM decreased viability 
by approximately 22% ± 5% (p < 0.05), 28% ± 1% (p < 0.01) and 47% ± 1% (p < 0.001), respectively 
(Figure 2B). Therefore, we show that the more aggressive C4-2 and ARCaPM cells displayed greater 
sensitivity to camalexin treatment than the lesser aggressive LNCaP and ARCaPE cells. 
Figure 2. The more aggressive C4-2 and ARCaPM prostate cancer cells are more sensitive 
to camalexin as compared to LNCaP and ARCaPE cells. Viability was determined using 
MTS proliferation assay at day 0 or day 3 for LNCaP and C4-2 (A), and ARCaPE and 
ARCaPM (B) cells treated with 10, 25 and 50 μM camalexin. Statistical analysis was done 
using ANOVA and Tukey’s Multiple Comparison as Post Hoc (* p < 0.05, ** p < 0.01, 
*** p < 0.001). Values were normalized to untreated controls and expressed as mean ± 
S.E.M (N = 3).  
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2.2. Camalexin Treatment of Prostate Cancer Cells Increases Protein Expression of the Lysosomal 
Protease CD, Bax and p53 Transcription Factor 
Previously, our laboratory has shown that camalexin treatment of prostate cancer cells produces 
oxidative stress-induced apoptosis with consequent increased caspase 3 activity and PARP cleavage [9]. 
Survey of the literature revealed that several agents and molecules of endogenous origin can induce 
lysosomal membrane permeabilization, among which ROS are the most important [37,38]. As a result, 
CD is translocated from the lysosomes to the cytosol and triggers a rapid change in Bax conformation 
together with insertion of this protein to the outer mitochondrial membrane [34]. CD and BAX protein 
expression was analyzed by western blot analysis in camalexin-treated (10, 25 and 50 µM) ARCaPE, 
ARCaPM, LNCaP and C4-2 cells. Camalexin treatments of LNCaP cells showed a tendancy towards 
increased protein expression of CD at the 10, 25 and 50 µM camalexin treatments, whilst Bax showed 
no significance in protein expression levels of treated versus untreated control cells (Figure 3A). 
However, for C4-2 cells, camalexin treatments significantly increased protein expression of CD  
(25 and 50 µM treatments, *** p < 0.001, ** p < 0.01 respectively) and BAX protein (10, 25 and 50 µM 
treatments, ** p < 0.01, *** p < 0.001, *** p < 0.001 respectively) as compared to the untreated 
control cells (Figure 3B). In ARCaPE cells, no significant levels of CD protein expression were noted 
for untreated control, 10 and 25 µM camalexin treatments, while at 50 µM treatment there was a 
tendency toward increased expression although there was no statistical significance noted (Figure 3C). 
At 25 µM camalexin treatment only, significant increase in Bax protein expression was noted  
(* p < 0.05) in ARCaPE cells (Figure 3C), although at 50 µM camalexin treatment there is a strong 
tendency towards increased expression as compared to untreated control cells (Figure 3C). In ARCaPM 
cells, however, 10 and 25 µM camalexin treatments induced significant increased protein expression of 
CD (*** p < 0.001) and BAX (10 and 50 µM treatments, ** p < 0.01, * p < 0.05 respectively) vs. the 
untreated control cells (Figure 3D). At 25 µM camalexin treatment of ARCaPM cells, the data showed 
increased Bax protein expression level when compared to the untreated control cells (Figure 3D).  
Wu et al., has demonstrated that p53 accumulates in cells subsequent to oxidative stress and can bind 
the CD promoter gene, and thus CD can participate in p53-dependent apoptosis [26]. Because we saw 
increased CD protein expression levels subsequent to camalexin treatments in our cells we decided to 
further investigate whether its trans-gene p53 may also be involved in the induced stress response. 
Western blot analysis showed that LNCaP and C4-2 cells at 25 and 50 µM camalexin treatments 
produced increased p53 protein expression when compared with the untreated control cells (Figure 3A,B). 
ARCaPE cell lysates did not display significant alterations in expression of p53 protein subsequent to 
camalexin treatments (Figure 3C). However, ARCaPM cell lysates showed significant increase in p53 
protein expression at 10, 25 and 50 µM camalexin-treatments (*** p < 0.001, * p < 0.05, and  
** p < 0.01) respectively (Figure 3D). Overall, our data shows that camalexin increases p53, CD and 
BAX expression, which are proteins involved in apoptosis and the effect is more pronounced in the 
ARCaPM and C4-2 cells as compared to ARCaPE and LNCaP cells, respectively. 
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Figure 3. Camalexin leads to increased expression of CD, Bax, and p53 protein in prostate 
cancer cell lines. Western Blot analysis was performed to examine CD, Bax and p53 
protein expression following exposure of LNCaP (A) and C4-2 (B), ARCaPE (C), 
ARCaPM (D) cells to various doses of camalexin for 3 days. β-actin was used as loading 
control. Densitometry was performed for each Western Blot using Image J Software 
(National Institutes of Health). Data are representative of at least 3 independent 
experiments and statistical analysis was done using ANOVA and Tukey’s Multiple 
Comparison as Post Hoc (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
 
Molecules 2014, 19 3994 
 
 
Figure 3. Cont. 
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2.3. Camalexin Shifts Subcellular Localization of CD from the Lysosome to the Cytosol 
A significant amount of hydrogen peroxide is produced in the mitochondria subsequent to oxidative 
stress and is able to diffuse into the lysosomes where ferruginous material delivered by autophagy is 
accumulated, resulting in Fenton-type reaction and production of highly reactive hydroxyl radicals [39]. 
These radicals cause lipid peroxidation of lysosomal membrane and subsequent leakage of proteases 
into the cytosol. In this way oxidative stress from the mitochondria is amplified with the help of redox-
active iron-rich lysosomes [40,41]. The role of CD in apoptosis has been defined previously [25,26] 
and using immunocytochemistry, we analyzed CD localization within cells following camalexin 
treatments. We detected granular staining of CD in C4-2 untreated control cells depicting its location 
within intact lysosomes (Figure 4A). After 24 h camalexin treatment only, fluorescence staining for 
CD was more diffuse, indicating its translocation from the lysosomes to the cytosol of C4-2 cells 
(Figure 4B). Co-treatment of camalexin with the ROS scavenger, N-acetylcysteine (NAC), produced 
increased granular staining almost similar to the untreated cells suggesting that it could reverse in part, 
the effects of camalexin (Figure 4C). Therefore, camalexin not only increases CD expression but also 
leads to its leakage from the lysosome to the cytoplasm through increased ROS production. 
Figure 4. Camalexin exposure in C4-2 cells induces release of lysosomal enzymes to the 
cytosol. CD localization was analyzed by Immunofluorescence analysis in C4-2 untreated 
(A), treated with 25 μM camalexin (B) or 25 μM camalexin and 10 mM NAC for 24 h (C). 
CD in untreated C4-2 cells  appears  punctuated in intact lysosomes while camalexin 
treatment led to more diffuse staining depicting CD release into cytosol. Co-treatment with 
NAC increased punctuated staining similar to untreated control cells. 
 
2.4. NAC Abrogates Camalexin-Mediated Increased p53, Bax and CD Protein Expression in Prostate 
Cancer Cells 
Oxidative stress has been shown to be responsible for lysosomal membrane destabilization with 
consequent permeabilization and leakage of proteases into the cytosol [40]. The ROS scavenger NAC 
was added to camalexin-treated C4-2 cells and p53, Bax and CD protein expression assessed via western 
blot analysis. The results strongly indicated decreased expression of p53 and Bax, and significant 
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abrogation of CD protein expression (** p < 0.01) by co-treatment of cells with NAC (Figure 5). 
Hence, camalexin utilizes oxidative stress to induce p53, Bax and CD protein expression. 
Figure 5. NAC abrogates the effects of camalexin-mediated p53, Bax and CD protein 
expression. C4-2 cells were treated with 25 μM camalexin or 25 μM camalexin plus  
10 mM NAC for 3 days. Western blot analysis was done to examine p53, Bax and mature 
CD protein expression. Treatment for 3 days indicated that NAC could inhibit p53, Bax 
and CD protein expression when combined with 25 μM camalexin. β-Actin was used as 
loading control and densitometry of protein expression assessed for treated versus 
untreated control cells. Data are representative of at least 3 independent experiments. 
Statistical analysis was done using ANOVA and Tukey’s Multiple Comparison as Post 
Hoc (** p < 0.01).  
 
2.5. Pepstatin A, a CD Inhibitor, Antagonizes Camalexin-Mediated Decrease in Cell Viability, and Its 
Promotion of Pro-Apoptotic Protein Expression 
We utilized the potent peptide inhibitor of CD activity, pepstatin A (Pep A), to confirm the role of 
this protease in camalexin-induced apoptosis in prostate cancer cells. We observed after 3 days that 
camalexin-mediated decrease in cell viability was blocked significantly by co-treatment with 100 µM 
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Pep A plus 25 or 50 μM camalexin in C4-2 cells (Figure 6A). Additionally, treatment of C4-2 cells 
with Pep A significantly antagonized camalexin-mediated increase in Bax and PARP cleavage protein 
expression without significantly affecting p53 levels (Figure 6B). Hence, Pep A functions downstream 
of CD and our studies imply that p53 must be acting upstream of CD since it is not significantly 
affected by Pep A.  
Figure 6. Pepstatin A abrogates the effects of camalexin-mediated decrease in cell viability 
and PARP cleavage. C4-2 cells were treated with 25 and 50 μM camalexin only, or 25 and 
50 μM camalexin plus 100 μM Pep A for 3 days and cell viability assayed using the MTS 
proliferation assay (A). Western blot analysis was done to examine p53, CD and cleaved 
PARP protein expression in untreated, camalexin-treated and camalexin plus Pep A- treated 
C4-2 cells, along with the densitometry of protein expression (B). Treatment for 3 days 
indicated that Pep A could significantly inhibit camalexin-mediated decrease in cell viability 
and increase in Bax and cleaved PARP protein expression, but does not significantly alter 
p53 and CD protein expression. Statistical analysis was done using ANOVA and Tukey’s 
Multiple Comparison as a Post Hoc Test. Values were expressed as mean ± S.E.M 
normalized to untreated controls, and 25 μM camalexin vs. 25 μM camalexin + 100 μM 
Pep A (* p < 0.05, ** p < 0.01). (N = 3). β-Actin was used as loading control and data are 
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Figure 6. Cont. 
 
2.6. Discussion 
The lysosomal pathway of apoptosis involves partial lysosomal membrane permeabilization (LMP) 
with subsequent release of cathepsins into the cytosol [19,42]. Resistance of cancer cells to 
chemotherapy is often considered to involve decreased sensitivity to apoptosis, and therefore alternate 
pathways to induce cell death in resistant tumors are highly demanded [43]. Hence, lysosomal cell 
death represents an alternate pathway where released cathepsins can activate apoptosis or execute 
apoptosis-like cell death independent of the caspases [44–46]. We have previously shown that 
camalexin decreases cell viability in prostate cancer cells by induction of oxidative stress leading to 
apoptosis [9]. Similarly, Mezencev et al. has shown that camalexin-induced apoptosis in Jurkat T 
leukemia cells occurred via increased ROS and involve mitochondrial superoxide generation 
evidenced by increased MitoSOX™ staining [47]. In this report we show that camalexin may also 
utilize the lysosomal pathway involving CD. We showed that camalexin decreased cell viability in 
ARCaPE and ARCaPM prostate cancer cell lines in a concentration-dependent manner and was more 
potent in ARCaPM cells. This would make camalexin a potential therapeutic agent for aggressive 
prostate cancer and we have previously shown that it does not affect normal prostate epithelial cells [9]. 
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Camalexin-induced cell death in ARCaPE, ARCaPM, LNCaP and C4-2 prostate cancer cells is 
accompanied by Lysosomal Membrane Permeability as evidenced by increased CD protein expression 
in treated vs. untreated control cells. Additionally, immunocytochemical analysis of camalexin-treated 
C4-2 cells displayed diffuse staining for CD vs. punctuated staining in lysosomes for untreated control, 
indicating this protease release into the cytosol. The addition of NAC to the camalexin-treated cells, 
displayed increased punctated staining verifying increased CD retention within lysosomes and hence 
lysosomal membrane stabilization. CD has been discovered as a key mediator of apoptosis induced by 
several apoptotic agents including oxidative stress [27–31,48]. Its role in apoptosis has been linked to 
lysosomal release of its mature form (33 kDa) into the cytosol, activation of Bax [34], and in turn 
leading to mitochondrial release of cytochrome c into the cytosol [27–30]. 
Our data reveals increased Bax protein expression in camalexin-treated prostate cancer cell lines. 
Mounting evidence points to Bax and other pro-apoptotic family members as central regulators of the 
release of proteins from the mitochondrial intermembrane space. Bax overexpression in cells or the 
addition of purified recombinant Bax directly to isolated mitochondria triggers release of cytochrome c 
into the cytosol [49,50] with subsequent activation of procaspases 9 and 3 [28]. Immuno-electron 
microscopy has confirmed that Bax can directly insert into the lysosomal membrane during 
staurosporine treatment of fibroblasts [20]. Additionally, CD has two binding sites at its promoter 
region for the p53 transcription factor and can participate in p53-dependent apoptosis [27]. Moreover, 
p53 can localize to the mitochondrial membrane and can trigger mitochondrial membrane 
permeabilization (MMP) by direct interaction with Bcl-2 proteins [51–54], and also can promote  
Bax-mediated MMP through transcriptional upregulation of BH3-only-domain proteins Puma and  
Noxa [55]. Hence in our model of camalexin-induced apoptosis in prostate cancer cells via oxidative 
stress-induction involving lysosomal protease CD, increased p53 protein expression may function as 
an amplification loop in the death pathway. 
In order to further demonstrate that camalexin is exerting its effects on CD through ROS, co- 
treatment of C4-2 cells with the antioxidant NAC decreased CD translocation to the cytosol and 
protein expression.  We further attempted to highlight the role of CD in camalexin-induced apoptosis 
by pretreatment of cancer cells with its known peptide inhibitor pepstatin A (Pep A). Camalexin-
mediated decrease in cell viability, increase in Bax protein levels and PARP cleavage was antagonized 
by cotreatment of cells with Pep A. Again, studies have shown that Pep A partially delayed the apoptosis 
induced by oxidative stress [30] or when Pep A was co-microinjected with CD in fibroblasts [32]. 
These authors have therefore evidenced CD’s key role in apoptosis via its catalytic activity.  
3. Experimental  
3.1. Reagents and Antibodies 
Growth media RPMI 1640 (1  with L-glutamine, and without L-glutamine and phenol red), and 
penicillin-streptomycin were from Mediatech Inc. (Manassas, VA, USA). Fetal bovine serum (FBS) 
and charcoal/dextran treated FBS (DCC-FBS) were from Hyclone (South Logan, UT, USA). T-media 
was from Gibco by Life Technologies Corporation (Grand Island, NY, USA). Trypsin /EDTA was 
from Mediatech, Inc. MTS Cell Titer 96 Aqueous One Solution reagent was from Promega 
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Corporation (Madison, WI, USA). Camalexin (40 mM in absolute ethanol) was kindly provided by our 
collaborator Roman Mezencev of Georgia Institute of Technology (Atlanta, GA, USA) and was 
synthesized as described previously [8]. N-acetylcysteine (NAC) and mouse monoclonal anti-human 
actin antibody were from Sigma-Aldrich Inc. (St. Louis, MO, USA). Rabbit monoclonal anti-cleaved 
PARP and Bax primary antibody were from Cell Signaling Technology, Inc. (Danvers, MA, USA). 
Goat polyclonal anti-cathepsin D and p53 primary antibody, and, donkey anti-goat HRP and were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). HRP conjugated sheep anti-mouse, donkey anti-
rabbit secondary antibodies, and the Enhanced Chemiluminescence (ECL) western blotting detection 
reagent were from GE Healthcare UK Ltd. (Buckinghamshire, UK). Nitrocellulose membranes were 
from Bio-Rad Life Sciences Research (Hercules, CA, USA).  
3.2. Cell Lines and Culture 
Human prostate cancer cell line ARCaPE, an epithelial cell line and ARCaPM the more highly 
metastatic and mesenchymal cell line were all derived from parental ARCaP cells [35] and utilized in 
these experiments (a kind gift from Dr Leland Chung, Cedars-Sinai Medical Center, Los Angeles, CA, 
USA). They were cultured in T-media supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM  
L-glutamine, 50 µg/mL penicillin and 100 µg/mL streptomycin. Additionally, we utilized LNCaP cells 
from American Type Culture Collection (Manassas, VA, USA) with lesser metastatic potential and its 
more aggressive subline C4-2 cells (a kind gift from Dr Leland Chung). LNCaP and C4-2 cells were 
routinely cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS),  
2 mM L-glutamine, 50 µg/mL penicillin and 100 µg/mL streptomycin. They were grown to 70% 
confluence in 95% air, 5% CO2 humidified incubator at 37 °C, and routinely passaged using 0.05% 
Trypsin/EDTA solution. For all experimental conditions RPMI 1640 without L-glutamine and phenol 
red and supplemented with 5% dextran charcoal stripped FBS (DCC-FBS) was used.  
3.3. Cell Viability Assay 
ARCaPE, ARCaPM, LNCaP and C4-2 cells were plated at a density of 2,000 cells per well in  
96-well plates and allowed to attach overnight. Camalexin (10, 25 and 50 µM) were added to cells and 
allowed to incubate at 37 °C in a humidified 5% CO2 atmosphere for 0 through 5 days and then 
viability assessed daily using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay according 
to supplier’s protocol. For cathepsin D activity inhibition studies, C4-2 cells were treated with 25 or  
50 µM camalexin alone or in combination with 100 µM pepstatin A for 0 and 3 days and then cell 
viability assessed.  
3.4. Western Blot Analysis 
Western blot was performed as described previously [36]. Briefly, cells were plated at a density of  
2 × 106 cells in 75 cm2 flasks, and allowed to attach overnight. Prior to treatments, ARCaPE and 
ARCaPM cells were serum-starved in serum-free and phenol red free RPMI medium overnight, while 
LNCaP and C4-2 cells were serum-starved for 4 h. Cells were then lysed with buffer containing  
1 × RIPA, with protease inhibitors (aprotinin 0.1 mg/mL, PMSF 1 mM, leupeptin 0.1 mM, pepstatin A 
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0.1 mM) and phosphatase- inhibitor (10 mM sodium orthovanadate) and centrifuged at 13,000 rpm. 
Total protein content was determined using Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL, USA) following protocol as per manufacturer’s specifications. Cell lysates (40–50 µg) 
were subjected to SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and then subsequently 
transferred to pure nitrocellulose membrane. Western blot analysis for CD, Bax, cleaved-PARP and 
p53 protein expression was then performed. Anti-mouse, anti-goat and anti-rabbit IgG horseradish 
peroxidase in blocking solution (5% nonfat milk in TBS-Tween 20) was employed as secondary 
antibodies for chemiluminescent detection. Blots were visualized with chemiluminescence ECL 
detection system (Pierce, Rockford, IL, USA) and analyzed using FUJIFILM LAS 3000 imager and 
dark room x-ray film to observe protein expression. To evaluate protein loading, membranes were 
immediately stripped with Restore ™ Western Blot Stripping Buffer (Thermo Scientific) and reprobed 
for β-actin as a loading control. Densitometry of protein expression relative to untreated control cells 
was evaluated using ImageJ Software (National Institutes of Health, Bethesda, MD, USA).  
3.5. Immunocytochemistry (ICC) 
When C4-2 cells reached 60%–80% confluence, 2 × 103 cells were plated into 16 well chamber 
slides (Bio-Tek, Nunc, Winooski, VT, USA). Cells were serum-starved for 4 h, and then left untreated, 
treated with 25 or 50 µM camalexin, or 25 or 50 µM camalexin plus 10 mM NAC for 24 h. The media 
was removed and 200 µL of equal parts per volume of methanol/ethanol was added for 5 min at room 
temp for fixation. Methanol/ethanol was gently removed and the slides were washed 3 × 5 min with  
1 × PBS and 50 µL of protein blocking solution (Dako, Camarillo, CA, USA) was added per well for 
10 min at room temp. Blocking solution was drained off with a tissue and 50 µL of goat anti-CD 
primary antibody (1:50 or 1:100) (in Dako antibody diluent solution,) was added per well for 1 h at 
room temp. Slides were washed 3 × 5 min with commercial 1 × TBS-T (Dako), and then incubated 
with Texas red anti-goat secondary antibody in the dark for 1 h at room temp. Slides were briefly 
dipped into double deionized water, incubated with DAPI (1 µg/mL) for 5 min at room temp in the 
dark. Slides were washed 3 × 5 min with 1 × TBS-T mounted using Fluorogel mounting medium 
(Electron Microscopy Sciences, Hatfield, PA, USA). Slides were placed in a container covered with 
foil and left to dry overnight in the dark. Fluorescence microscopy was performed using AxioZeiss 
(Rel 4.8) fluorescence microscopy and images were captured at 20x magnification.  
3.6. Statistical Analysis 
Statistical analysis was performed using ANOVA and Tukey’s Multiple Comparison Test as  
Post-Hoc test from Graph Pad Prizm3 software (GraphPad Software Inc., San Diego, CA, USA);  
* p < 0.05, ** p < 0.01, *** p < 0.001 were considered significant. Multiple experiments were 
performed in replicates of 3.  
4. Conclusions  
Considerable progress has been made in understanding the role of lysosomes and lysosomal 
proteases in the apoptotic pathways [56]; however, the exact mechanisms of lysosomal membrane 
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permeabilization and its consequences are still not well understood. Although there are supporting data 
for camalexin ability to generate ROS in cells [9,47], the mechanism(s) involved are yet to be 
elucidated. We have attempted here to show the role of mature CD in camalexin-induced apoptosis via 
oxidative stress-induction in prostate cancer cells. Therefore, targeting lysosomes can provide a great 
therapeutic strategy in cancer cells because not only do they trigger apoptosis, but also can suppress 
autophagic flux which starves these cells and thus can sensitize them to chemotherapeutic agents [56]. 
Hence, camalexin treatment of especially metastatic prostate cancer cells in combination with current 
chemotherapeutic agents may provide a very vital therapeutic option. 
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